Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 666 results for kidney or kidneys or renal

  1. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for glycemic control

    Topic prioritisation

  2. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.

  3. Published

    The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.

  4. Risk assessment, referral criteria and shared care: What is the accuracy of the 4-variable Kidney Failure Risk Equation in children and young people living in the UK?

    referral criteria and shared care: What is the accuracy of the 4-variable Kidney Failure Risk Equation in children and young people...

  5. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    be at risk of other problems such as damage to the blood vessels in your kidneys or eyes. The higher your blood pressure, the more...

  6. Cystatin-C equations: What is the diagnostic accuracy of cystatin-C equations to estimate GFR as a measurement of kidney function in adults, young people and children in the UK?

    diagnostic accuracy of cystatin-C equations to estimate GFR as a measurement of kidney function in adults, young people and children in...

  7. What is the relative effectiveness and cost effectiveness of different oral fluids and different oral fluid regimens, both with and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury?

    and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury? Any explanatory notes(if applicable) Why the...

  8. Intravenous fluid therapy in children and young people in hospital (NG29)

    This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.

  9. Diabetes: admission rates (renal replacement therapy) (IND45)

    This indicator covers admission rates for renal replacement therapy in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG63

  10. Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)

    NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne withdrew its evidence submission.

    Sections for TA838

  11. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

  12. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

    Topic prioritisation

  13. Diabetes: complications (IND9)

    This indicator covers the proportion of adults with a diagnosis of diabetes who have a recording of myocardial infarction (MI), stroke and/or end stage kidney disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG12

  14. Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.

  15. Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

    Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.